EANS-News: Epigenomics and Predictive Biosciences Extend Licensing Deal for Prostate Cancer Test

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Licensing Agreements/Company Information/Molecular diagnostics

BERLIN, PHILADELPHIA, PA and LEXINGTON, MA, November 16, 2010 (euro
adhoc) - Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer
diagnostics company, and Predictive Biosciences, a commercial stage,
fully-integrated developer of novel molecular diagnostic cancer
assays and a provider of anatomic pathology laboratory products and
services, today announced that they have extended their licensing
agreement for the prostate cancer biomarker GSTP1, originally signed
in April 2009. Under the terms of the original agreement, Predictive
Biosciences had obtained rights to develop a prostate cancer test
incorporating this well known DNA methylation biomarker and an option
to license GSTP1 for commercialization of this test as a laboratory
service in the United States. Based on strong continued progress in
developing the test, Predictive Biosciences has now executed this
option, triggering an undisclosed one-time license fee to
Epigenomics. Epigenomics will also be entitled to royalties on future
sales generated with Predictive Biosciences' prostate cancer test,
which is still in development.

"Prostate cancer diagnosis suffers from poor specificity of PSA
screening," said Geert Nygaard, CEO of Epigenomics. "We are therefore
delighted that Predictive Biosciences will be using our biomarker to
develop a test to improve the diagnostic follow-up of patients with
high PSA."

"We have been very impressed with the quality of methylated GSTP1 as
a biomarker for prostate cancer," said Peter Klemm, Ph.D., President
and Chief Executive Officer of Predictive Biosciences. "This
biomarker will provide a valuable contribution to the portfolio of
tests we are commercializing in the field of urologic oncology."

Prostate cancer is one of the most prevalent forms of cancer and the
leading cause of cancer death in men in the U.S., with more than
230,000 cases diagnosed annually and more than 1 million prostate
biopsies performed each year. The methylation of the GSTP1 gene is
well established as a biomarker of prostate cancer and a test that
detects methylated GSTP1 DNA in urine or tissue, in combination with
conventional histopathology, may enable a more accurate diagnosis.

-Ends-

Contact Epigenomics AG

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368
pr@epigenomics.com
www.epigenomics.com

Contact Predictive Biosciences

Predictive Biosciences:
Andy Hu, M.D.
+1 (781) 402-1780 x202
www.predictivebiosci.com

About Epigenomics

Epigenomics AG is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation
biomarkers, Epigenomics' tests on the market and in development for
colorectal, lung, and prostate cancer aim at aiding in an earlier and
more accurate diagnosis of these diseases, thereby potentially
increasing the patient's chances of survival.

For development and global commercialization of IVD test products,
Epigenomics pursues a dual business strategy in which direct
commercialization of proprietary diagnostic test products is combined
with non-exclusive licensing to diagnostic industry players with
broad customer access. Strategic diagnostics industry partners
include Abbott Molecular, Sysmex Corporation, Quest Diagnostics
Incorporated, ARUP Laboratories, Inc., and Warnex Laboratories, Inc.
for diagnostics test products and services, and QIAGEN N.V. for
sample preparation solutions and research products.

The company is headquartered in Berlin, Germany, and has a wholly
owned subsidiary, Epigenomics Inc., in Seattle, WA, USA. For more
information, please visit Epigenomics' website at www.epigenomics.com

About Predictive Biosciences

Predictive Biosciences is a fully?integrated developer of novel
molecular diagnostic cancer assays and an urology?focused provider of
anatomic pathology laboratory products and services. Leveraging a
portfolio of patented biomarkers and clinical approaches, the company
is building a unique portfolio of assays for cancer management, first
targeted at bladder and prostate cancer. Predictive Biosciences'
commercial division, OncoDiagnostic Laboratory (ODL), is a Clinical
Laboratory Improvement Act (CLIA)?certified anatomic pathology and
molecular diagnostics lab with a national sales force serving
urologists and other subspecialty physicians. For additional
information, please visit www.predictivebiosci.com

Epigenomics' legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States of America. The analytical and
clinical performance characteristics of any product based on this
technology which may be sold at some future time by Epigenomics in
the USA have not been established.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade